Tools chosen: polymarket_direct polymarket_related kalshi_related claude_news gdelt_news wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a low-base-rate event: WHO has formally used the word "pandemic" only for 2009 H1N1 and COVID-19 in the past ~50 years, and its current legal instrument is the PHEIC/pandemic emergency declaration under the amended IHR. The key research tasks are anchoring on the Polymarket price, checking cross-venue prices, and assessing current live threats (H5N1/H5N5 avian influenza, mpox clade Ib, Marburg/Ebola, measles, unknown outbreaks) plus any WHO procedural changes that would make a 'pandemic' declaration more likely.

# Current state As of the research cutoff (~July 2026), no WHO "pandemic" declaration or new IHR "pandemic emergency" (the 2024-amendment top tier) has occurred in 2026. The active elevated-risk events are a growing DRC/Uganda Ebola (Bundibugyo virus) PHEIC (declared 17 May 2026) and continued sporadic H5N1/H5N5 avian flu spillover with no sustained human-to-human transmission. Polymarket's near-identical market prices YES at 7.5%. # Timeline of key events - 2024-08: WHO declares mpox clade Ib a PHEIC (confirmed, prior year). - 2025-09-19: Amended IHR enters into force, creating a new "pandemic emergency" declaration tier distinct from PHEIC; several major states (US, Germany, Canada, others) have rejected the amendments (confirmed, WHO/EJIL Talk!). - 2025-09-05: WHO lifts the mpox clade Ib PHEIC; standing recommendations extended to Aug 2026; clades I/II still circulating in Africa (confirmed, WHO DON587). - 2025-11-15/20: 71st global H5-family human case reported (US); CDC confirms first-ever human H5N5 case; no further cases in contact tracing, no human-to-human transmission evidence (confirmed, WHO DON590/CDC). - 2025-11 to 2026-01: Marburg outbreak in Ethiopia (14 cases, 9 deaths); declared over 2026-01-26 (confirmed, Wikipedia/Ethiopian govt). - 2026-03-04: WHO Emergency Committee (44th meeting) reaffirms polio PHEIC remains warranted (confirmed). - 2026-05-17: WHO declares a new PHEIC for Ebola (Bundibugyo virus) in DRC/Uganda — 17th DRC Ebola outbreak since 1976 (confirmed, WHO DON602). - 2026-06: Multiple countries (India, Kenya, others) activate Ebola preparedness/screening measures; no confirmed imported cases (reported, GDELT/news aggregators). - 2026-07-01: Ebola outbreak reaches 1,406–1,460 confirmed cases, 438–452 deaths, ~38 new cases/day — sustained but contact-transmitted, EU risk assessed "very low" (confirmed, WHO/ECDC). - Through mid-2026: No disease has been escalated to the new "pandemic emergency" tier; no WHO official has used the word "pandemic" for any 2026 event (confirmed by absence in sources). # Event Will the WHO declare any disease a pandemic between Jan 1 and Dec 31, 2026? # Outcomes to forecast - Yes - No # Kalshi market anchor No comparable Kalshi market found (kalshi_related: 0 matches for "pandemic," "bird flu," "H5N1"). No direct Kalshi price was returned in this research; treat Polymarket as the best available cross-market anchor: **YES 7.5%**, up +1.0% over 7 days, down −1.0% over 30 days, range 5.5%–13.5% over 90 days, volume ~$958K. # Sub-question answers 1. **Polymarket price/trajectory & Kalshi comparison** — Polymarket YES = 7.5%, mild uptrend recently (+1% 7d), off a 90-day high of 13.5%. A related "Hantavirus pandemic in 2026?" market prices YES at only 3.55% on much higher volume ($17.4M), suggesting the market treats disease-specific pandemic declarations as very unlikely. No Kalshi equivalent market was found (kalshi_related, 0 hits). 2. **WHO's formal pandemic mechanism** — WHO has explicitly used "pandemic" only twice historically (2009 H1N1, 2020 COVID-19); under the 2005 IHR there is no formal "pandemic" declaration category — WHO instead issues PHEICs. The 2024 IHR amendments (in force since 2025-09-19) added a new "pandemic emergency" tier, but this is a higher bar than PHEIC and has never been invoked (claude_news, WHO). 3. **H5N1/H5N5 status** — First-ever human H5N5 case confirmed Nov 2025 (US); WHO total H5-subtype human cases ~993 (2003–Dec 2025) with 477 deaths; no sustained human-to-human transmission documented anywhere; WHO/global risk assessment remains low to low-moderate for occupationally exposed groups (WHO DON590, DON575, Wikipedia). 4. **Active PHEICs / escalating outbreaks** — Polio PHEIC remains active (reaffirmed March 2026). Mpox PHEIC ended Sept 2025 (standing recommendations only). A new Ebola (Bundibugyo virus) PHEIC was declared 17 May 2026 in DRC/Uganda, expanding (1,400+ cases by July 2026) but transmission is contact-based, not airborne; EU/ECDC risk rated "very low." No coronavirus or "Disease X" cluster reported (claude_news, WHO DON602). 5. **Resolution ambiguity** — The question specifies WHO must "declare... a pandemic," not merely a PHEIC or pandemic emergency. Historically PHEICs (polio, Ebola, mpox) have not been labeled "pandemics" by WHO. If resolvers require the literal word "pandemic," current PHEICs (polio, Ebola) would not qualify. No prior-year version's resolution history was found in this research. 6. **Defensible base rate** — Code-execution analysis: strict "pandemic"-word base rate ≈ 3.5%/yr (2 events in 56 years); broad "any PHEIC" base rate ≈ 34%/yr (8 events in 19 years). With H5N1/Ebola elevated-risk adjustment (1.3–1.5×): strict ≈ 4.5–5.2%; broad ≈ 42–47%; blended estimate ≈ 20–29%, reflecting interpretation uncertainty. # Key facts (high-confidence, factual) 1. [Polymarket] Current YES price 7.5%, volume ~$958K, 90-day range 5.5–13.5%. 2. [WHO DON602] New Ebola (Bundibugyo virus) PHEIC declared 2026-05-17, DRC/Uganda, expanding through July 2026. 3. [WHO DON590] First-ever human H5N5 case (Nov 2025); no human-to-human transmission found. 4. [WHO DON587] Mpox PHEIC lifted 2025-09-05. 5. [UNMC] Polio PHEIC reaffirmed active as of 2026-03-04. 6. [WHO/EJIL] Amended IHR "pandemic emergency" tier in force since 2025-09-19; never invoked as of mid-2026. 7. [Wikipedia] Since 2005, 9 PHEICs declared; only 2 (H1N1 2009, COVID-19 2020) were labeled "pandemics" by WHO. # Cross-market signals - Kalshi related: none found. - Polymarket: this exact market at 7.5% YES; comparable "Hantavirus pandemic in 2026?" at 3.55% YES (much higher volume, suggesting disease-specific pandemic bets trade far lower than the generic "any disease" question). - Sportsbook implied: n/a. # Analyst opinions and speculation - claude_news synthesis: "Bottom line... No WHO 'pandemic emergency'... has been declared for any disease as of mid-2026," implying low near-term likelihood absent major escalation. - H5N1/H5N5 is repeatedly flagged (Wikipedia, WHO) as "the world's largest pandemic threat" long-term, but current transmission remains bird-to-human only. # Directional lean per outcome - **Yes**: Elevated background risk (new Ebola PHEIC, H5N5 first human case, persistent H5N1 circulation, historical PHEIC frequency ~34%/yr) supports non-trivial tail risk; amended IHR framework theoretically allows escalation. - **No**: No sustained human-to-human transmission of any novel pathogen; WHO has used the explicit word "pandemic" only twice since 1970s; current Ebola outbreak is contact-transmitted and regionally contained per ECDC; no "pandemic emergency" tier invoked; Polymarket and analogous markets price this at single-digit probabilities. # Gaps / unknowns - No confirmed Kalshi-specific price for direct comparison. - Unclear how strictly resolvers will interpret "declares...a pandemic" (literal word vs. PHEIC vs. new pandemic emergency tier) — this is the single largest source of forecast variance. - No visibility into Sept–Dec 2026 developments beyond July 2026 cutoff. # Calibration anchors - Polymarket YES price (anchor): 7.5%. - Related Polymarket market (disease-specific pandemic): 3.55%. - Historical base rate: strict ~3.5–5%/yr; broad (any PHEIC) ~34–47%/yr; blended ~20–29%/yr.

1. Both forecasters anchor tightly to Polymarket's 7.5% (landing at 6% and 8%) without seriously grappling with the brief's own "blended estimate ≈ 20–29%" from the base-rate analysis, which explicitly weighted resolution-ambiguity risk — this is a large unaddressed discrepancy between the quantitative base-rate work and the market anchor that neither rationale reconciles. 2. Neither forecast meaningfully engages with sub-question 5 (resolution ambiguity): if resolvers accept a PHEIC or the new "pandemic emergency" tier as satisfying "declares a pandemic," the active Ebola PHEIC and any H5N5 escalation could trigger YES well above single digits — this is flagged in the brief as "the single largest source of forecast variance," yet both converge near identical low numbers as if ambiguity were resolved. 3. Both treat the Polymarket "Hantavirus pandemic" market (3.55%) as confirming low pricing for disease-specific pandemic bets, but that market is not directly comparable (single-pathogen vs. any-disease question) — using it to reinforce the 6-8% range risks a reference-class error, since the actual question here is broader ("any disease") and thus should logically price higher than a single-pathogen contract. 4. Neither forecaster explicitly addresses the ~5 months remaining post-cutoff with an ongoing, expanding Ebola outbreak (+38 cases/day, no plateau evidenced) and a first-ever H5N5 human case — both dismiss escalation risk on current trajectory without quantifying tail probability of the Ebola outbreak crossing into sustained wider transmission or the H5N5 situation generating a cluster before year-end. 5. Both forecasts sit almost exactly on the current Polymarket price with minimal independent adjustment (6% and 8% vs 7.5% anchor), showing insufficient differentiation or sensitivity analysis — given the brief's own acknowledgment of "interpretation uncertainty" spanning 3.5% to 47%, a medium-confidence forecast clustering so narrowly around the anchor may be underconfident in exploring the distribution's true width. 6. Neither forecast discusses the potential for WHO messaging/political incentives — given that major states have rejected the amended IHR pandemic-emergency tier (US, Germany, Canada), WHO may be strategically disincentivized from invoking it even if epidemiologically warranted, which could push probability even lower than the market suggests, an angle absent from both rationales.

7% (medium confidence)

Yes: 7% No: 93%

The exact-question Polymarket contract trades at 7.5% YES with ~$958K volume, and crucially that price already incorporates the known, active Ebola (Bundibugyo) PHEIC and the first human H5N5 case — meaning the market has effectively priced the resolution-ambiguity question and concluded that PHEICs do not satisfy 'declares a pandemic.' That resolves the critique's central objection: the brief's 20–29% 'blended' figure double-counts interpretation uncertainty that informed traders have already adjudicated, and the strict historical base rate (2 uses of the word in ~56 years, ~3.5%/yr) plus never-invoked pandemic-emergency tier both point to single digits. Offsetting factors roughly cancel: ~5 remaining months with an expanding but contact-transmitted Ebola outbreak and possible H5 clustering argue mildly upward, while WHO's political disincentive to invoke a tier rejected by the US, Germany and Canada argues downward. I therefore settle essentially on the anchor at 7% YES, splitting the two forecasts and preserving a genuine tail for a novel airborne cluster emerging in Q4 2026.

Total pipeline time: 285.4s